drugset / Trial / NCT03448081

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

NCT03448081

Phase 2 Completed 73 enrolled Sienna Biopharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 2 study evaluating safety, tolerability, and efficacy of SNA-120 ointment when administered topically with calcipotriene ointment for the treatment of pruritus and psoriasis.

Timeline

Start
2018-02-12
Primary completion
2018-11-21
Completion
2018-12-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator CT327 Unknown 0.5 % Topical
Comparator Calcipotriol Small molecule 0.005 %

Indications